옵션 체인은 다양한 행사가격과 만기일에 대한 Intensity Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Intensity Therapeutics에 대한 시장 심리를 평가합니다..

Intensity Therapeutics (NASDAQ:INTS) 주식, 옵션 체인

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

<p>Guggenheim  analyst Steven Forbes   maintains Floor &amp; Decor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) with a Buy and lowers the price target from $115 to $100.</p>


News

Price Target

Analyst Ratings

Guggenheim Maintains Buy on Floor & Decor Hldgs, Lowers Price Target to $100

<p>B. Riley Securities  analyst Josh Nichols   reiterates OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) with a Buy and raises the price target from $221 to $255.</p>


Reiteration

OSIS

B. Riley Securities Reiterates Buy on OSI Systems, Raises Price Target to $255

<p>CIBC  analyst Kevin Chiang   maintains Canadian National Railway (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNR#TSX">CNR</a>) with a Neutral and lowers the price target from C$157 to C$146.</p>


TSX:CNR

CIBC Maintains Neutral on Canadian National Railway, Lowers Price Target to C$146

<p>B. Riley Securities  analyst Randy Binner   maintains New York Mortgage Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYMT#NASDAQ">NYMT</a>) with a Buy and raises the price target from $8 to $9.</p>


NYMT

B. Riley Securities Maintains Buy on New York Mortgage Trust, Raises Price Target to $9

WIIM

PHAT

Phathom Pharmaceuticals shares are trading lower after HC Wainwright maintained a Buy rating on the stock and lowered its price target from $28 to $20.

<p>B. Riley Securities  analyst Mayank Mamtani   reiterates Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $422 to $460.</p>


MDGL

B. Riley Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $460

<p>Guggenheim  analyst Michael Schmidt   maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Buy and lowers the price target from $32 to $16.</p>


ARVN

Guggenheim Maintains Buy on Arvinas, Lowers Price Target to $16

<p>B. Riley Securities  analyst Hal Goetsch   reiterates Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Buy and lowers the price target from $29 to $17.</p>


FLYW

B. Riley Securities Reiterates Buy on Flywire, Lowers Price Target to $17

<p>B. Riley Securities  analyst Anna Glaessgen   reiterates Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and lowers the price target from $70 to $60.</p>


B. Riley Securities Reiterates Neutral on Estee Lauder Cos, Lowers Price Target to $60

UBER

Uber Technologies And Momenta Announce Strategic Agreement To Introduce Autonomous Vehicles To Uber Platform, In International Markets Outside Of US And China

<p><strong>Altimmune Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares jumped 8.5% to $5.61 on Friday, ahead of <a href="https://www.benzinga.com/pressreleases/25/05/g45130957/altimmune-to-present-at-upcoming-easl-international-liver-congress-2025">next week&#8217;s presentation</a> at the European Association for the Study of the Liver International Liver Congress 2025. The stock also trended on Stocktwits as investor interest surged.</p>
<p><strong>What To Know:</strong> The Maryland-based biopharma company will present analyses of its investigational drug pemvidutide in treating metabolic dysfunction-associated steatotic liver disease. The company says the data leverages the novel MASH Resolution Index, a non-invasive metric that predicts histologic improvements in liver health. </p>
<p>Altimmune's findings will be shared in <a href="https://www.benzinga.com/pressreleases/25/05/g45130957/altimmune-to-present-at-upcoming-easl-international-liver-congress-2025">two poster sessions</a> during the congress in Amsterdam, including a guided tour on May 8 and a general session on May 10.</p>
<p><strong>Dr. Shaheen Tomah</strong>, Director of Clinical Development, will present the results, as investors will be watching for meaningful advancements in non-invasive liver disease assessment.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/25/05/45168400/apple-stock-falls-after-cook-warns-of-900m-tariff-impact">Apple Stock Falls After Cook Warns of $900M Tariff Impact</a></strong></p>
<h2 class="wp-block-heading">How To Buy ALT Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Altimmune&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ALT has a 52-week high of $11.16 and a 52-week low of $3.56.</p>


What's Going On With Altimmune (ALT) Stock Today?

<p>CIBC  analyst Stephanie Price   maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $33 to $31.</p>


OTEX

CIBC Maintains Neutral on Open Text, Lowers Price Target to $31

<p>Wedbush  analyst Alicia Reese   reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Outperform and maintains $100 price target.</p>


ROKU

Wedbush Reiterates Outperform on Roku, Maintains $100 Price Target

<p>B. Riley Securities  analyst Anna Glaessgen   reiterates Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Buy and lowers the price target from $4 to $3.</p>


COOK

B. Riley Securities Reiterates Buy on Traeger, Lowers Price Target to $3

<p><a href="https://www.wsj.com/world/china/beijing-weighs-fentanyl-offer-to-u-s-to-start-trade-talks-287cf233" title="https://www.wsj.com/world/china/beijing-weighs-fentanyl-offer-to-u-s-to-start-trade-talks-287cf233">https://www.wsj.com/world/china/beijing-weighs-fentanyl-offer-to-u-s-to-start-trade-talks-287cf233</a></p>


Macro Economic Events

Macro Notification

Politics

Global

Economics

General

"Beijing Weighs Fentanyl Offer To U.S. To Start Trade Talks; Addressing The Trump Team's Gripes Over China's Role In The Fentanyl Crisis Could Let Both Sides Soften Trade Stance" - WSJ

<p><strong>Reddit, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares rose on Friday after the company reported better-than-expected first-quarter earnings on Thursday after <a href="https://www.benzinga.com//node/45157434">the market closed.</a></p>
<p><strong>What To Know: </strong>The company reported earnings per share of 13 cents, beating the consensus estimate of 2 cents. In addition, Reddit reported sales of $392.36 million, beating the consensus estimate of $370.01 million, and representing a 61% year-over-year increase.</p>
<p>The company broke down revenue further, stating that ad revenue increased 61% year-over-year to $358.6 million, while other revenue increased 66% to $33.7 million.</p>
<p>The company sees second-quarter sales from $410 million to $430 million, versus the consensus estimate of $395.48 million.</p>
<p>&#8220;Over 400 million people now come to Reddit each week—because when you want real opinions, you turn to real people,&#8221; said <strong>Steve Huffman</strong>, Co-Founder and CEO of Reddit. &#8220;20 years in, I have never been more excited about Reddit&#8217;s future than I am now. We&#8217;re growing and building a more valuable platform for community and human perspective.&#8221;</p>
<p>Following the earnings report, Needham analyst <strong>Laura Martin</strong> maintained a Buy rating on Reddit and raised the price target from&nbsp;$135&nbsp;to&nbsp;$145. JMP Securities analyst<strong> Andrew Boone</strong> maintained a Market Outperform rating on Reddit and raised the price target from&nbsp;$155&nbsp;to&nbsp;$180.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/markets/eurozone/25/05/45167255/euro-area-q1-gdp-beats-expectations-driven-by-exports-before-us-tariffs">Euro Area Q1 GDP Beats Expectations, Driven By Exports Before US Tariffs</a></strong></p>
<p><strong>RDDT Price Action:</strong> At the time of writing, Reddit shares are trading 1.53% higher at $120.61, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a></p>
<p><em>Image: via Shutterstock</em></p>


Movers

RDDT

What's Going On With Reddit Shares Friday?

<p>Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) is preparing to release its quarterly earnings on Monday, 2025-05-05. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Inspire Medical Systems to report an <strong>earnings per share</strong> (EPS) of $-0.23.</p>
<p>Inspire Medical Systems bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.44, which was followed by a 1.66% increase in the share price the next day.</p>

<p><img src="https://www.benzinga.com/files/images/story/2025/1746201711_0.png" alt="eps graph" /></p>
<h3>Performance of Inspire Medical Systems Shares</h3>
<p>Shares of Inspire Medical Systems were trading at $157.9 as of May 01. Over the last 52-week period, shares are down 37.8%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Inspire Medical Systems</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Inspire Medical Systems.</p>
<p>The consensus rating for Inspire Medical Systems is Outperform, derived from 9 analyst ratings. An average one-year price target of $221.89 implies a potential 40.53% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Glaukos, Integer Holdings and Teleflex, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Glaukos, with an average 1-year price target of $146.7, suggesting a potential 7.09% downside.</li>
<li>Analysts currently favor an Buy trajectory for Integer Holdings, with an average 1-year price target of $145.71, suggesting a potential 7.72% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Teleflex, with an average 1-year price target of $151.0, suggesting a potential 4.37% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Glaukos, Integer Holdings and Teleflex, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inspire Medical Systems</td>
<td>Outperform</td>
<td>24.52%</td>
<td>$203.73M</td>
<td>5.08%</td>
</tr>
<tr>
<td>Glaukos</td>
<td>Buy</td>
<td>1.10%</td>
<td>$76.86M</td>
<td>-2.37%</td>
</tr>
<tr>
<td>Integer Holdings</td>
<td>Buy</td>
<td>7.26%</td>
<td>$120.32M</td>
<td>-1.39%</td>
</tr>
<tr>
<td>Teleflex</td>
<td>Neutral</td>
<td>2.78%</td>
<td>$439.92M</td>
<td>-3.12%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Inspire Medical Systems ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, Inspire Medical Systems stands out for its strong revenue growth and gross profit performance compared to its peers.</p>
<h3>About Inspire Medical Systems</h3>
<p>Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.</p>
<h3>Inspire Medical Systems: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Inspire Medical Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>24.52%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Inspire Medical Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>14.69%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Inspire Medical Systems's ROE excels beyond industry benchmarks, reaching <strong>5.08%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Inspire Medical Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.39%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Inspire Medical Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.05</strong>.</p>
<p><a href="https://www.benzinga.com/quote/INSP/earnings"><strong>To track all earnings releases for Inspire Medical Systems visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

INSP

A Peek at Inspire Medical Systems's Future Earnings

<p>B. Riley Securities  analyst Kalpit Patel   maintains Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Neutral and lowers the price target from $17 to $14.</p>


BCYC

B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $14

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Arista Networks</strong>.</p>
<p>Looking at options history for Arista Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) we detected 23 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 26% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $194,163 and 19, calls, for a total amount of $1,283,433.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $45.0 and $130.0 for Arista Networks, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Arista Networks's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Arista Networks's substantial trades, within a strike price spectrum from $45.0 to $130.0 over the preceding 30 days.</p>
<h3>Arista Networks Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746201657_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.5</td>
<td>$8.9</td>
<td>$9.4</td>
<td>$105.00</td>
<td>$298.3K</td>
<td>3.9K</td>
<td align="right">337</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$17.9</td>
<td>$17.9</td>
<td>$17.9</td>
<td>$90.00</td>
<td>$134.8K</td>
<td>613</td>
<td align="right">75</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$90.00</td>
<td>$98.0K</td>
<td>533</td>
<td align="right">153</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$47.8</td>
<td>$47.8</td>
<td>$47.8</td>
<td>$45.00</td>
<td>$81.2K</td>
<td>0</td>
<td align="right">17</td>
</tr>
<tr>
<td>ANET</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$31.8</td>
<td>$31.3</td>
<td>$31.8</td>
<td>$75.00</td>
<td>$76.3K</td>
<td>739</td>
<td align="right">24</td>
</tr>
</tbody>
</table>
</p>
<h3>About Arista Networks</h3>
<p>Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.</p>
<p>After a thorough review of the options trading surrounding Arista Networks, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Arista Networks's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 3,853,085, the ANET's price is up by 3.94%, now at $91.3. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 4 days.</li>
</ul>
<h3>What The Experts Say On Arista Networks</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $77.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Rosenblatt upgraded its action to Neutral with a price target of $85.<br />
&#x2A; Consistent in their evaluation, an analyst from Rosenblatt keeps a Sell rating on Arista Networks with a target price of $55.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Arista Networks, targeting a price of $76.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Arista Networks, targeting a price of $100.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Arista Networks, maintaining a target price of $73. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Arista Networks with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

ANET

Decoding Arista Networks's Options Activity: What's the Big Picture?

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Datadog</strong>.</p>
<p>Looking at options history for Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 30% with bearish.</p>
<p>From the overall spotted trades, 9 are puts, for a total amount of $1,955,354 and 4, calls, for a total amount of $124,655.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $85.0 to $119.0 for Datadog over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Datadog's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Datadog's whale trades within a strike price range from $85.0 to $119.0 in the last 30 days. </p>
<h3>Datadog Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746201652_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/09/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$100.00</td>
<td>$714.3K</td>
<td>436</td>
<td>2.1K</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$12.85</td>
<td>$12.6</td>
<td>$12.65</td>
<td>$105.00</td>
<td>$624.9K</td>
<td>215</td>
<td>494</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$1.5</td>
<td>$1.27</td>
<td>$1.51</td>
<td>$91.00</td>
<td>$143.1K</td>
<td>1.7K</td>
<td>2</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$8.55</td>
<td>$8.2</td>
<td>$8.2</td>
<td>$110.00</td>
<td>$142.6K</td>
<td>1.0K</td>
<td>174</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.7</td>
<td>$5.65</td>
<td>$5.7</td>
<td>$105.00</td>
<td>$99.7K</td>
<td>839</td>
<td>274</td>
</tr>
</tbody>
</table>
</p>
<h3>About Datadog</h3>
<p>Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.</p>
<p>Having examined the options trading patterns of Datadog, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Datadog Standing Right Now?</h3>
<ul>
<li>With a volume of 1,844,211, the price of DDOG is up 0.92% at $107.3. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 4 days.</li>
</ul>
<h3>Expert Opinions on Datadog</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $122.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Datadog with a target price of $115.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Datadog, targeting a price of $120.<br />
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on Datadog with a target price of $135.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for Datadog, targeting a price of $125.<br />
&#x2A; Consistent in their evaluation, an analyst from DA Davidson keeps a Buy rating on Datadog with a target price of $115. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Datadog, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


DDOG

Datadog Unusual Options Activity

Press Releases

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Offerings

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

INTS

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aprea Therapeutics

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

HCW Biologics

iBio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

MetaVia

Mainz Biomed

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Polyrizon

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Intensity Therapeutics

Intensity Therapeutics (INTS) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌